Physician profile
Michael W Stavinoha
NPI 1154345593
$8,253.28
in general payments reported to CMS, 2019-2025
30 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $762 · 2021: $1,531 · 2022: $1,334 · 2023: $1,449 · 2024: $1,781 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,725 · Gift: $327 · Education: $17.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,725.27 |
| Gift | $327.24 |
| Education | $17.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,270.51 | 2019-2025 | Mavyret, Rinvoq, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,103.66 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Merck Sharp & Dohme LLC | $955.21 | 2019-2024 | Dificid |
| Janssen Biotech, INC. | $624.78 | 2019-2025 | Stelara, Tremfya, Simponi |
| Braintree Laboratories, INC. | $526.84 | 2020-2024 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $472.58 | 2019-2025 | Entyvio |
| Celgene Corporation | $443.58 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $361.94 | 2021-2023 | |
| Redhill Biopharma INC. | $349.66 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Pfizer INC. | $307.20 | 2022-2025 | |
| Gilead Sciences, INC. | $248.68 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $240.37 | 2023-2024 | Voquezna |
| Evoke Pharma, INC. | $233.39 | 2020-2023 | Gimoti |
| Intra-Sana Laboratories | $171.81 | 2021-2022 | |
| Apollo Endosurgery US INC | $145.64 | 2023 | Overstitch Endoscopic Suturing System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $136.24 | 2023 | Nexpowder |
| E.R. Squibb & Sons, L.L.C. | $124.40 | 2024 | |
| Conmed Corporation | $101.66 | 2024 | Conmed Generators |
| Intercept Pharmaceuticals, INC. | $95.60 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $91.65 | 2024-2025 | Zenpep |
| Perspectum Diagnostics LTD | $57.42 | 2022 | |
| Lilly USA, LLC | $30.92 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $26.61 | 2025 | Rezdiffra |
| Amgen INC. | $23.55 | 2023 | Amjevita, Avsola |
| Ironwood Pharmaceuticals, INC | $21.04 | 2021 | |
| Ferring Pharmaceuticals INC. | $20.61 | 2020 | |
| Phadia US INC. | $18.61 | 2023 | Immunocap |
| Ipsen Biopharmaceuticals, INC | $17.40 | 2024 | Iqirvo |
| Celltrion USA INC. | $17.32 | 2024 | Zymfentra |
| Alfasigma USA, INC. | $14.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stavinoha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.